Safety and antiviral activity of JTK-652: A novel HCV infection inhibitor

Antiviral Therapy

Volumn 15, Issue 5, 2010, Pages 765-773

  De Bruijne, Joep ^a   Bergmann, Jilling F ^b   Weegink, Christine J ^a   Van Nieuwkerk, Carin M J ^c   De Knegt, Robert J ^b   Komoda, Yasumasa ^d   De Rooij, Jeroen J Van De Wetering ^e   Van Vliet, Andre ^e   Jansen, Peter L M ^a   Molenkamp, Richard ^a   Schinkel, Janke ^a   Reesink, Hendrik ^a   Janssen, Harry L A ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

^d JAPAN TOBACCO INC   (Japan)

^e PRA Health Sciences   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE PROTEIN; GLYCOPROTEIN E1; GLYCOPROTEIN E2; JTK 652; PYRIDAZINE DERIVATIVE; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN HEPG2; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE; VESICULAR STOMATITIS; VIRUS INHIBITION;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; CELL LINE, TUMOR; CELLS, CULTURED; DOUBLE-BLIND METHOD; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HEPATOCYTES; HUMANS; MALE; MIDDLE AGED; PYRIDAZINES; RNA, VIRAL; TREATMENT OUTCOME;

EID: 77957361845     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1606     Document Type: Article

References (27)

1. World Health Organization. Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6:35-47.
2. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345:41-52.
3. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36:S35-S46.
4. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
5. Hadziyannis SJ, Sette H, Jr., Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
6. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965. (Pubitemid 32913521)
7. Lindenbach BD, Evans MJ, Syder AJ, et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309:623-626.
8. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285:110-113.
9. Bartosch B, Cosset FL. Studying HCV cell entry with HCV pseudoparticles (HCVpp). Methods Mol Biol 2009; 510:279-293.
10. Barth H, Schafer C, Adah MI, et al. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 2003; 278:41003-41012.
11. Cormier EG, Durso RJ, Tsamis F, et al. L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus. Proc Natl Acad Sci U S A 2004; 101:14067-14072. (Pubitemid 39305031)
12. Evans MJ, von Hahn T, Tscherne DM, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007; 446:801-805. (Pubitemid 46582027)
13. Monazahian M, Bohme I, Bonk S, et al. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol 1999; 57:223-229. (Pubitemid 29069727)
14. Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. Science 1998; 282:938-941.
15. Ploss A, Evans MJ, Gaysinskaya VA, et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009; 457:882-886.
16. Scarselli E, Ansuini H, Cerino R, et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002; 21:5017-5025.
17. Buonocore L, Blight KJ, Rice CM, Rose JK. Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins. J Virol 2002; 76:6865-6872. (Pubitemid 41246201)
18. Lagging LM, Meyer K, Owens RJ, Ray R. Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus. J Virol 1998; 72:3539-3546.
19. Matsuura Y, Tani H, Suzuki K, et al. Characterization of pseudotype VSV possessing HCV envelope proteins. Virology 2001; 286:263-275.
20. Hirashima S, Suzuki T, Ishida T, et al. Benzimidazole derivatives bearing substituted biphenyls as hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors: structure-activity relationship studies and identification of a potent and highly selective inhibitor JTK-109. J Med Chem 2006; 49:4721-4736.
21. Pietschmann T. Virology: final entry key for hepatitis C. Nature 2009; 457:797-798.
22. Harris HJ, Farquhar MJ, Mee CJ, et al. CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol 2008; 82:5007-5020. (Pubitemid 351657061)
23. Zhang J, Randall G, Higginbottom A, Monk P, Rice CM, McKeating JA. CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol 2004; 78:1448-1455. (Pubitemid 38095855)
24. Timpe JM, Stamataki Z, Jennings A, et al. Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 2008; 47:17-24. (Pubitemid 351171037)
25. Valli MB, Serafino A, Crema A, et al. Transmission in vitro of hepatitis C virus from persistently infected human B-cells to hepatoma cells by cell-to-cell contact. J Med Virol 2006; 78:192-201. (Pubitemid 43132563)
26. Witteveldt J, Evans MJ, Bitzegeio J, et al. CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol 2009; 90:48-58.
27. Matsuura Y, Komoda Y, Tani H, et al. Human fibroblast growth factor receptor 5 is a novel candidate entry receptor for HCV. 12th International Symposium on Hepatitis C Virus and Related Viruses. 2-6 October 2005, Montreal, QC, Canada. Abstract 153.